Previous Close | 126.00 |
Open | 0.00 |
Bid | 127.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 0.00 - 0.00 |
52 Week Range | |
Volume | |
Avg. Volume | 771,189 |
Market Cap | 829.534M |
Beta (5Y Monthly) | 0.25 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.25 |
Earnings Date | Jun 20, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jun 20, 2019 |
1y Target Est | 245.33 |
Freeline Therapeutics (FRLN) is set to be acquired by Syncona Ltd. The transaction is expected to be closed in the first quarter of 2024. Shares rise.
Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s initial proposal on October 18, in an all-cash transaction Based on extensive evaluation of available strategic and financing options, Freeline’s independent directors unanimously recommend transaction as best value for shareholders Syncona to provide $15 million in convertible debt financing to cover Freeline’s near-term capital needs and support ongoing adva